You are here

Dying for FDA Reform

OnPoint

Title

Dying for FDA Reform

Full Document Available in PDF

This year, Congress is considering a variety of legislative changes that would substantially affect the regulation of pharmaceutical drugs.  There is growing momentum for congressional action to address several perceived drug safety problems, but all of the proposals under consideration would harm, not improve, patient safety by making it more difficult to get promising new drugs approved and into the hands of doctors and patients.  These ill-conceived policies would also increase the already astronomical costs of bringing these medicines to market, raise prices, and reduce incentives for developers to undertake experimental projects.